Asha Therapeutics | Reshaping Healthcare

Patients are our priority, designing curative medicines is our mission

Our primary focus is patients suffering from currently incurable life altering diseases. The disruptive PRISM™ Platform is a leading-edge novel physics-based drug design engine that has resulted in a pipeline of clinic-ready assets for the treatment of diseases across multiple clinical areas including neurology, oncology, and infectious disease.

Curative medicines are important, as is access to them

While our primary goal is to develop breakthrough disease modifying therapeutics, we are equally focused on ensuring these therapeutics reach the broadest patient population. We go beyond our key disease indications to leverage our technology platform PRISM™ through partnerships and key public health programs to ensure we are making the largest impact as possible by reshaping healthcare.

#healthcare & #healthequity

News & Press Releases

Business Wire

Mar 9

Asha Therapeutics to Present at AD/PD™ 2024 International Conference and Announces Clinical Development Plan for Lead Programs Anticipated to Enter Clinical Trials this Year

CINCINNATI--(BUSINESS WIRE)--Asha Therapeutics (Asha), (www.ashatherapeutics.com), a life sciences company, is leveraging its...

PR Newswire

Sep 22, 2023

Asha Therapeutics Selected as a BLUE KNIGHT™ Company by Johnson & Johnson Innovation and BARDA

Asha Therapeutics (Asha), (www.ashatherapeutics.com), a biopharmaceutical company revolutionizing the traditional multi-year drug...

JnJ Innovation

Sep 1, 2023

Inside the Innovation Arena – A Recap of Our BLUE KNIGHT™ QuickPitch: Activating for the Future

August 31, 2023 - Earlier this week, innovation took center stage at the BLUE KNIGHT™ QuickPitch: Activating for the Future. 10...

Asha TX

Jun 23, 2023

Asha TX to present breakthrough data for ASHA-044 tareting Beta-Catenin in colorectal cancer at NGIO

Asha Therapeutics will be presenting new data at the 6th Annual Next-Gen Immuno-oncology Conference showing robust efficacy of their...

Asha TX

Jun 10, 2023

Targeting mitochondria in ME/CFS and Long Haul COVID with ASHA-091

Asha Therapeutics presented exciting new data for their lead Parkinson's Disease therapeutic ASHA-091 in one of its secondary indications...

Asha TX

Apr 13, 2023

Asha Therapeutics Announces the Presentation of New Data on ASHA-1007, a Novel VHL Recruiter for TPD

See Full Press Release Here Asha Therapeutics presented their novel VHL recruiter technology at Third Annual Ligase Targeting Drug...

More News & Press Releases

Solving the Most Challenging Diseases
Asha's Therapeutic Focus Areas

Neurology & Neurodegneration

Alzheimer's Disease | Parkinson's Disease | ALS

Asha's Solution: ASHA-091 & ASHA-624

Learn More

Oncology & Immuno-oncology

Colorectal Cancer | Hepatocellular Carcinoma | Melanoma

Asha's Solution: ASHA-044

Learn More

Infectious Disease & Post-viral Illness

ME/CFS | Long COVID | Antibiotic Resistance

Asha's Solution: ASHA-091 & Undisclosed

Learn More

A Revolutionary & Paradigm Shifting Technology
The PRISM™ Design Platform

Central to Asha's efforts to identify and drug difficult to hit targets with high disease relevance is our proprietary novel physics-based drug design platform, PRISM™

Learn More

ARL

Partner with us to leverage the power of
The PRISM™ Design Platform
to solve your targets of interest

Partnership Inquiry

Patients are our priority, designing curative medicines is our mission

Solving complex diseases with our breakthrough PRISM™ platform

Explore our disease modifying medicines

Looking through PRISM™ to see the Future of healthcare

Curative medicines are important, as is access to them

News & Press Releases